Luiz H Araujo1, Philip E Lammers, Velmalia Matthews-Smith, Rosana Eisenberg, Adriana Gonzalez, Ann G Schwartz, Cynthia Timmers, Konstantin Shilo, Weiqiang Zhao, Thanemozhi G Natarajan, Jianying Zhang, Ayse Selen Yilmaz, Tom Liu, Kevin Coombes, David P Carbone. 1. *Department of Internal Medicine, James Thoracic Center, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio; †Department of Internal Medicine, Meharry Medical College, Nashville, Tennessee; ‡Department of Internal Medicine, Baptist Center for Cancer Care, Columbus, Mississippi; §Department of Pathology, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee; ‖Pathology Associates of Saint Thomas, Nashville, Tennessee; ¶Department of Internal Medicine, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan; #GenomOncology, Cleveland, Ohio; ††Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio; and ‡‡Department of Biomedical Informatics, Biomedical Informatics Shared Resource, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio.
Abstract
INTRODUCTION: The mutational profile of non-small-cell lung cancer (NSCLC) has become an important tool in tailoring therapy to patients, with clear differences according to the population of origin. African Americans (AAs) have higher lung cancer incidence and mortality than Caucasians, yet discrepant results have been reported regarding the frequency of somatic driver mutations. We hypothesized that NSCLC has a distinct mutational profile in this group. METHODS: We collected NSCLC samples resected from self-reported AAs in five sites from Tennessee, Michigan, and Ohio. Gene mutations were assessed by either SNaPshot or next generation sequencing, and ALK translocations were evaluated by fluorescence in situ hybridization. RESULTS: Two hundred sixty patients were included, mostly males (62.3%) and smokers (86.6%). Eighty-one samples (31.2%) were squamous cell carcinomas. The most frequently mutated genes were KRAS (15.4%), epidermal growth factor receptor (EGFR, 5.0%), PIK3CA (0.8%), BRAF, NRAS, ERBB2, and AKT1 (0.4% each). ALK translocations were detected in two nonsquamous tumors (1.7%), totaling 61 cases (23.5%) with driver oncogenic alterations. Among 179 nonsquamous samples, 54 (30.2%) presented a driver alteration. The frequency of driver alterations altogether was lower than that reported in Caucasians, whereas no difference was detected in either EGFR or KRAS mutations. Overall survival was longer among patients with EGFR mutations. CONCLUSIONS: We demonstrated that NSCLC from AAs has a different pattern of somatic driver mutations than from Caucasians. The majority of driver alterations in this group are yet to be described, which will require more comprehensive panels and assessment of noncanonical alterations.
INTRODUCTION: The mutational profile of non-small-cell lung cancer (NSCLC) has become an important tool in tailoring therapy to patients, with clear differences according to the population of origin. African Americans (AAs) have higher lung cancer incidence and mortality than Caucasians, yet discrepant results have been reported regarding the frequency of somatic driver mutations. We hypothesized that NSCLC has a distinct mutational profile in this group. METHODS: We collected NSCLC samples resected from self-reported AAs in five sites from Tennessee, Michigan, and Ohio. Gene mutations were assessed by either SNaPshot or next generation sequencing, and ALK translocations were evaluated by fluorescence in situ hybridization. RESULTS: Two hundred sixty patients were included, mostly males (62.3%) and smokers (86.6%). Eighty-one samples (31.2%) were squamous cell carcinomas. The most frequently mutated genes were KRAS (15.4%), epidermal growth factor receptor (EGFR, 5.0%), PIK3CA (0.8%), BRAF, NRAS, ERBB2, and AKT1 (0.4% each). ALK translocations were detected in two nonsquamous tumors (1.7%), totaling 61 cases (23.5%) with driver oncogenic alterations. Among 179 nonsquamous samples, 54 (30.2%) presented a driver alteration. The frequency of driver alterations altogether was lower than that reported in Caucasians, whereas no difference was detected in either EGFR or KRAS mutations. Overall survival was longer among patients with EGFR mutations. CONCLUSIONS: We demonstrated that NSCLC from AAs has a different pattern of somatic driver mutations than from Caucasians. The majority of driver alterations in this group are yet to be described, which will require more comprehensive panels and assessment of noncanonical alterations.
Authors: M A Phelps; T E Stinchcombe; J S Blachly; W Zhao; L J Schaaf; S L Starrett; L Wei; M Poi; D Wang; A Papp; J Aimiuwu; Y Gao; J Li; G A Otterson; W J Hicks; M A Socinski; M A Villalona-Calero Journal: Clin Pharmacol Ther Date: 2014-04-29 Impact factor: 6.875
Authors: Fouad Zakharia; Analabha Basu; Devin Absher; Themistocles L Assimes; Alan S Go; Mark A Hlatky; Carlos Iribarren; Joshua W Knowles; Jun Li; Balasubramanian Narasimhan; Steven Sidney; Audrey Southwick; Richard M Myers; Thomas Quertermous; Neil Risch; Hua Tang Journal: Genome Biol Date: 2009-12-22 Impact factor: 13.583
Authors: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber Journal: N Engl J Med Date: 2004-04-29 Impact factor: 91.245
Authors: Rafael Rosell; Teresa Moran; Cristina Queralt; Rut Porta; Felipe Cardenal; Carlos Camps; Margarita Majem; Guillermo Lopez-Vivanco; Dolores Isla; Mariano Provencio; Amelia Insa; Bartomeu Massuti; Jose Luis Gonzalez-Larriba; Luis Paz-Ares; Isabel Bover; Rosario Garcia-Campelo; Miguel Angel Moreno; Silvia Catot; Christian Rolfo; Noemi Reguart; Ramon Palmero; José Miguel Sánchez; Roman Bastus; Clara Mayo; Jordi Bertran-Alamillo; Miguel Angel Molina; Jose Javier Sanchez; Miquel Taron Journal: N Engl J Med Date: 2009-08-19 Impact factor: 91.245
Authors: Haiying Cheng; H Dean Hosgood; Lei Deng; Kenny Ye; Christopher Su; Janaki Sharma; Yuanquan Yang; Balazs Halmos; Roman Perez-Soler Journal: Clin Lung Cancer Date: 2019-07-17 Impact factor: 4.785
Authors: Christine M Lusk; Donovan Watza; Greg Dyson; Douglas Craig; Valerie Ratliff; Angela S Wenzlaff; Fulvio Lonardo; Aliccia Bollig-Fischer; Gerold Bepler; Kristen Purrington; Shirish Gadgeel; Ann G Schwartz Journal: Clin Cancer Res Date: 2019-04-12 Impact factor: 12.531
Authors: Ting-Yuan David Cheng; Susanna M Cramb; Peter D Baade; Danny R Youlden; Chukwumere Nwogu; Mary E Reid Journal: J Thorac Oncol Date: 2016-06-27 Impact factor: 15.609
Authors: Joshua D Campbell; Christopher Lathan; Lynette Sholl; Matthew Ducar; Mikenah Vega; Ashwini Sunkavalli; Ling Lin; Megan Hanna; Laura Schubert; Aaron Thorner; Nicholas Faris; David R Williams; Raymond U Osarogiagbon; Paul van Hummelen; Matthew Meyerson; Laura MacConaill Journal: JAMA Oncol Date: 2017-06-01 Impact factor: 31.777
Authors: Rony F Arauz; Jung S Byun; Mayank Tandon; Sanju Sinha; Skyler Kuhn; Sheryse Taylor; Adriana Zingone; Khadijah A Mitchell; Sharon R Pine; Kevin Gardner; Eliseo J Perez-Stable; Anna M Napoles; Bríd M Ryan Journal: J Thorac Oncol Date: 2020-09-12 Impact factor: 15.609